araag2/HINT huggingface dataset:
Clinical trial NCT01197521 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: fostamatinib, fostamatinib, placebo, fostamatinib
SMILES: COC1=CC(NC2=NC=C(F)C(NC3=CC=C4OC(C)(C)C(=O)NC4=N3)=N2)=CC(OC)=C1OC, COC1=CC(NC2=NC=C(F)C(NC3=CC=C4OC(C)(C)C(=O)NC4=N3)=N2)=CC(OC)=C1OC, COC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC
Eligibility criteria:

        Inclusion Criteria:

          -  Active rheumatoid arthritis (RA) diagnosed after the age of 16

          -  Currently taking methotrexate

          -  6 or more swollen joints and 6 or more tender/painful joints (from 28 joint count) and
             either Erythrocyte Sedimentation Rate (ESR) blood result of 28mm/h or more, or
             C-Reactive Protein (CRP) blood result of 10mg/L or more

          -  At least one of the following: documented history of positive rheumatoid factor (blood
             test), current presence of rheumatoid factor (blood test), radiographic erosion within
             12 months prior to study enrolment, presence of serum anti-cyclic citrullinated
             peptide antibodies (blood test)

        Exclusion Criteria:

          -  Females who are pregnant or breast feeding

          -  Poorly controlled hypertension

          -  Liver disease or significant liver function test abnormalities

          -  Certain inflammatory conditions (other than rheumatoid arthritis), connective tissue
             diseases or chronic pain disorders

          -  Recent or significant cardiovascular disease

          -  Significant active or recent infection including tuberculosis

          -  Previous failure to respond to a TNF alpha antagonist, anakinra or previous treatment
             with other biological agent

          -  Severe renal impairment

          -  Neutropenia
Clinical trial NCT00614939 (phase 3, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: saxagliptin, placebo
SMILES: N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with type 2 diabetes

          -  Documented history of CrCl <50 ml/min within the 3 months prior to enrollment

          -  HbA1c ≥7.0% and ≤11.0%

        Exclusion Criteria:

          -  Type 1 diabetes, history of diabetic ketoacidosis or hyposmolar non-ketonic coma

          -  Previous or current treatment with any DPP-IV inhibitor and/or GLP-1 mimetic.
Clinical trial NCT00325442 (phase 3, status: completed)
Conditions: pulmonary hypertension
ICD codes: I27.0, I27.20, I27.21, I27.24, I27.29, P29.30, I27.22
Drugs: oral treprostinil (ut-15c) sustained release tablets, placebo
SMILES: [H][C@]12C[C@@H](O)[C@H](CC[C@@H](O)CCCCC)[C@@]1([H])CC1=C(C2)C(OCC(O)=O)=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Between 12 and 70 years of age, inclusive.

          -  Body weight at least 45 kg (approximately 100 pounds).

          -  PAH that is either idiopathic/heritable (including PAH associated with appetite
             suppressant/toxin use); PAH associated with repaired congenital systemic-to-pulmonary
             shunts (repaired ≥ 5 years); PAH associated with collagen vascular disease; or PAH
             associated with HIV.

          -  Baseline 6-minute walk distance between 150 and 450 meters, inclusive.

          -  Currently receiving an approved endothelin receptor antagonist and/or an approved
             phosphodiesterase-5 inhibitor for at least 90 days and on a stable dose for at least
             the last 30 days.

          -  Previous testing (e.g., right heart catheterization, echocardiography) consistent with
             the diagnosis of PAH.

          -  Reliable and cooperative with protocol requirements.

        Exclusion Criteria:

          -  Nursing or pregnant.

          -  Received a prostacyclin within the past 30 days.

          -  PAH due to conditions other than noted in the above inclusion criteria.

          -  History of uncontrolled sleep apnea, renal insufficiency, anemia, left sided heart
             disease, uncontrolled systemic hypertension, or parenchymal lung disease.

          -  Use of an investigational drug within 30 days of Baseline.
Clinical trial NCT00393458 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: indacaterol, formoterol, placebo to indacaterol, placebo to formoterol
SMILES: CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female adults ≥ 40 years, with a diagnosis of chronic obstructive pulmonary
             disease (COPD) according to Global Initiative for Chronic Obstructive Lung Disease
             (GOLD) guidelines 2005 and:

               1. Smoking history of at least 20 pack years

               2. Post-bronchodilator forced expiratory volume in 1 second (FEV1) < 80% and ≥ 30%
                  of the predicted normal value

               3. Post-bronchodilator FEV1/FVC (forced volume capacity) < 70% (Post refers to
                  within 30 minutes after inhalation of 400 μg of salbutamol)

                  Exclusion Criteria:

          -  Patients who were hospitalized for a COPD exacerbation in the 6 weeks prior to
             screening.

          -  Patients who had a respiratory tract infection within 6 weeks prior to screening.

          -  Patients with concomitant pulmonary disease.

          -  Patients with a history of asthma.

          -  Patients with diabetes type I or uncontrolled diabetes type II.

          -  Any patient with lung cancer or a history of lung cancer.

          -  Patients with a history of certain cardiovascular co-morbid conditions.

        Other protocol-defined inclusion/exclusion criteria applied to the study.
Clinical trial NCT01242748 (phase 3, status: terminated)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: degarelix, goserelin acetate
SMILES: CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=C(NC(N)=O)C=C1)NC(=O)[C@H](CC1=CC=C(NC(=O)[C@@H]2CC(=O)NC(=O)N2)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O, CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O
Reason stopped: 
    inadequate recruitment resulting in a too low patient number for collection of long term
    efficacy data.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Has given written consent prior to any trial-related activity is performed. (A
             trial-related activity is defined as any procedure that would not have been performed
             during the normal management of the patient).

          -  Has completed the CS35 trial.

        Exclusion Criteria:

          -  Has been withdrawn from the CS35 trial.

          -  Has had end of trial visit in CS35 prior to approval of the CS35A protocol.
Clinical trial NCT00626782 (phase 2/phase 3, status: completed)
Conditions: glaucoma
ICD codes: H40.9, Q15.0, B73.02, H40.823, H40.89, H44.513, H40.821
Drugs: ranibizumab, mitomycin (mmc)
SMILES: CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O, CO[C@]12[C@H]3N[C@H]3CN1C1=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  18 yrs or older

          -  patients requiring first time glaucoma filtering surgery

          -  phakic or pseudophakic

          -  must provide written informed consent and comply with study assignments

        Exclusion Criteria:

          -  Pregnant, lactation or premenopausal women not using adequate contraception.

          -  Previous glaucoma surgery, tube shunt surgery, pars plana vitrectomy, scleral buckle,
             penetrating keratoplasty.

          -  Abnormality preventing reliable applanation tonometry in each eye.

          -  Current infection or inflammation in either eye.

          -  Enrolled in another investigational study.
Clinical trial NCT00698581 (phase 3, status: terminated)
Conditions: epilepsy
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801
Drugs: brivaracetam, brivaracetam
SMILES: CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1, CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1
Reason stopped: 
    an interim analysis revealed the study was unlikely to attain a positive outcome for the
    efficacy analysis. no safety concerns were detected.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects from 16 to 75 years, both inclusive

          -  Well-characterized focal epilepsy or epileptic syndrome

          -  Subjects having at least 2 but not exceeding 40 partial onset seizures, whether or not
             secondarily generalized per 4 weeks during the 8-week Baseline Period

          -  Subjects on a stable dose of at least 1 but no more than 2 concomitant Antiepileptic
             Drugs (AEDs) with the second AED ≤ 50 % of the minimum recommended maintenance dose

        Exclusion Criteria:

          -  Seizure type IA non-motor as only seizure type

          -  History or presence of seizures occurring too frequently or indistinctly separated to
             be reliably counted during the 6 months preceding Visit 1 or during Baseline

          -  Other serious uncontrolled disease
Clinical trial NCT00282984 (phase 3, status: completed)
Conditions: smoking cessation
ICD codes: Y36.881S, Y36.891S, Y36.880S, Y36.881A, Y36.881D, Y36.890S, Y36.891A
Drugs: placebo, varenicline
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@]12C[C@]([H])(CNC1)C1=CC3=NC=CN=C3C=C21
Eligibility criteria:

        Inclusion Criteria:

          -  Participants must have stable, documented cardiovascular disease (including at least
             one of the following diagnosed > 2 months prior to the Screening visit - angina,
             myocardial infarction (MI), revascularization, transient ischemic attack (TIA), and
             peripheral vascular disease (PVD).

          -  Participants that smoke > 10 cigarettes / day.

        Exclusion Criteria:

          -  Participants with unstable cardiovascular disease

          -  Cardiovascular events in the past 2 months

          -  Moderate or severe chronic obstructive pulmonary disease (COPD)
Clinical trial NCT00113607 (phase 3, status: completed)
Conditions: ovarian cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: trabectedin, doxil, dexamethasone
SMILES: [H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4C=C(OC)C(O)=C5)C(=O)OC[C@H](N1[C@@H](O)[C@@H]1CC4=CC(C)=C(OC)C(O)=C4[C@H]2N1C)C1=C2OCOC2=C(C)C(OC(C)=O)=C31, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically proven epithelial ovarian cancer, epithelial fallopian tube cancer, or
             primary peritoneal cancer

          -  Prior treatment with only 1 platinum based chemotherapy regimen

          -  Eastern Cooperative Oncology Group status of not more than 2

          -  Progression more than 6 months after the start of initial chemotherapy treatment

        Exclusion Criteria:

          -  Treatment with more than 1 prior chemotherapy regimen

          -  Progression within 6 months after starting initial chemotherapy

          -  Prior exposure to anthracyclines

          -  Unwilling or unable to have central venous catheter

          -  Known clinically relevant central nervous system metastasis
Clinical trial NCT00252733 (phase 3, status: completed)
Conditions: type 1 diabetes
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: candesartan cilexetil
SMILES: CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Type 1 diabetes diagnosed before age of 36 years and in need for continuous insulin
             treatment within 1 year of diagnosis of diabetes are included.

          -  Duration of diabetes for > 1 year and < 15 years with stable diabetic therapy within
             last 6 months.

          -  Patients with untreated resting mean sitting SBP < 130 mmHg, mean sitting DBP < 85
             mmHg and with retinal photograph grading level 10/10 (on ETDRS severity scale).

        Exclusion Criteria:

          -  Patients with the following conditions are excluded from participation in the study:

          -  Cataract or media opacity of a degree which precludes taking gradable retinal
             photographs

          -  Angle closure glaucoma, which precludes pharmacological dilatation of the pupil

          -  History of retinopathy

          -  History or presence of clinical significant macular oedema (CSME)

          -  History or evidence of photocoagulation of the retina Other retinal conditions which
             may mask assessment, eg, retinal vein occlusion

          -  Positive micral dipstick test

          -  Presence of secondary diabetes

          -  Pregnant or lactating women or women of child bearing potential not practicing an
             adequate method of contraception

          -  Need of treatment with ACE-inhibitor

          -  Haemodynamically significant aortic or mitral valve stenosis

          -  Known renal artery stenosis or kidney transplantation

          -  Hypersensitivity to study drug

          -  Severe concomitant disease which may interfere with the assessment of the patient, eg,
             malignancy, as judged by the investigator
Clinical trial NCT01079806 (phase 3, status: completed)
Conditions: chronic hepatitis b virus, pediatric
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: entecavir, placebo
SMILES: CCOC(=O)C1=CC=C(N)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria

          -  Males and females, aged 2 to <18 years

          -  Hepatitis B surface antigen-positive

          -  Detectable hepatitis B e (HBe) antigen, and no detectable anti-HBe antibodies

          -  Alanine aminotransferase (ALT) 1.5 to <10 times the upper limit of normal at screening
             and within 8 to 24 weeks prior to screening

          -  Evidence of the presence of hepatitis B virus DNA at least 4 weeks before screening
             and >100,000 copies/mL at screening

        Key Exclusion Criteria

          -  Any prior therapy with entecavir

          -  At least 12 weeks of prior therapy with any nucleoside or nucleotide antiviral agent

          -  Therapy with interferon alpha, thymosin alpha, or nucleototide antiviral agents within
             24 weeks of screening

          -  Coinfection with HIV, hepatitis C virus, or hepatitis D virus

          -  Decompensated liver disease

          -  Liver transplant recipients

          -  Other forms of acute and chronic conditions which may cause increased ALT levels

          -  Children who were breastfed while their mothers received lamivudine or whose mothers
             received lamivudine during pregnancy
Clinical trial NCT00645515 (phase 3, status: terminated)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: ziprasidone, risperidone
SMILES: ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Reason stopped: 
    this study was terminated on november 20, 2003 because of poor recruitment. this study was not
    terminated due to safety/efficacy.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of schizophrenia

          -  CGI-S score of 4 or less at baseline

        Exclusion Criteria:

          -  Concurrent antipsychotic treatment

          -  Treatment with antidepressants or mood stabilizers within 2 weeks of randomization

          -  Acute exacerbation of schizophrenia within 3 months of baseline
Clinical trial NCT01134042 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: fluticasone furoate/vilanterol inhalation powder, fluticasone furoate inhalation powder, fluticasone propionate inhalation powder
SMILES: OCC1=C(O)C=CC(=C1)[C@@H](O)CNCCCCCCOCCOCC1=C(Cl)C=CC=C1Cl, [H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Outpatient at least 12 years of age

          -  Both genders; females of childbearing potential must be willing to use birth control
             method

          -  Pre-bronchodilator FEV1 of 40-90% predicted

          -  Reversibility FEV1 of at least 12% and 200mls

          -  Current asthma therapy that includes an inhaled corticosteroid for at least 12 weeks
             prior to first visit

        Exclusion Criteria:

          -  History of life-threatening asthma

          -  Respiratory infection or oral candidiasis

          -  Asthma exacerbation within 12 weeks

          -  Concurrent respiratory disease or other disease that would confound study
             participation or affect subject safety

          -  Allergies to study drugs, study drugs' excipients, medications related to study drugs

          -  Taking another investigational medication or medication prohibited for use during this
             study
Clinical trial NCT00324363 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: exenatide, placebo
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Treated with a stable dose of one of the following for at least 3 months prior to
             screening: * >=1000 mg/day immediate-release metformin; or metformin >=1000 mg/day and
             sulfonylurea; or sulfonylurea/metformin combination therapy.

          -  HbA1c between 7.1% and 11.0%, inclusive.

          -  Body Mass Index (BMI) >21 kg/m^2 and <35 kg/m^2.

        Exclusion Criteria:

          -  Have participated in this study previously, or any other study using exenatide or
             GLP-1 analogs.

          -  Have participated in an interventional, medical, surgical, or pharmaceutical study
             within 30 days of screening.

          -  Have characteristics contraindicating metformin or sulfonylurea use.

          -  Have been treated with exogenous insulin for more than 1 week within the 3 months
             prior to screening.

          -  Have used drugs for weight loss within 1 month of screening.
Clinical trial NCT00474058 (phase 3, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: rotigotine
SMILES: CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1
Eligibility criteria:

        Inclusion Criteria:

          -  Early and advanced Idiopathic Parkinson Disease with early morning motor impairment

        Exclusion Criteria:

          -  Atypical Parkinsonian syndromes
Clinical trial NCT00228462 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: seroquel (quetiapine)
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Stable schizophrenic patients who have provided written informed consent

          -  Patients 18 to 65 years old who remain clinically stable after switching to a stable
             dose of Seroquel (quetiapine).

        Exclusion Criteria:

          -  Patients with risk of suicide, other disorders or substance abuse that might interfere
             with the patient's ability to co-operate,

          -  Expected non-compliance to treatment

          -  Known diabetes mellitus,

          -  Contraindications,

          -  Intolerance or non-responsiveness to Seroquel or other safety issues.
Clinical trial NCT01040689 (phase 3, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: olodaterol (bi1744) low, placebo (for olodaterol bi1744), placebo (for tiotropium), olodaterol (bi1744) high, tiotropium 18 mcg
SMILES: COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1
Eligibility criteria:

        Inclusion criteria:

          -  Patients willing to participate with confirmed diagnosis of COPD

          -  40 years of age or older

          -  having a 10 pack year smoking history

          -  able to perform serial pulmonary function tests

          -  able to use both a Dry powder inhaler (DPI) and Respimat device

        Exclusion criteria:

          -  Significant other disease

          -  clinically relevant abnormal hematology, chemistry, or urinalysis

          -  history of asthma

          -  diagnosis of thyrotoxicosis

          -  paroxysmal tachycardia related to beta agonists

          -  history of MI within 1 year, cardiac arrhythmia, hospitalization for heart failure
             within 1 year

          -  active tuberculosis, cystic fibrosis, clinically evident bronchiectasis

          -  significant alcohol or drug abuse

          -  pulmonary resection

          -  taking oral beta adrenergics

          -  taking unstable oral steroids

          -  daytime oxygen

          -  enrolled in rehabilitation program

          -  enrolled in another study or taking investigational products

          -  pregnant or nursing women, women of child bearing potential not willing to use two
             methods of birth control

          -  those who are not willing to comply with pulmonary medication washouts